TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05095298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine, COVID19
Description: It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine, COVID19
Description: It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine, COVID19
Description: It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
Study: NCT05923697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AF-EMDR
Description: Investigational treatment~All participants receive four 90 min. AF-EMDR sessions within a timeframe of two weeks following the baseline phase. The AF-EMDR treatment will be provided by the principal investigators, a level II EMDR therapist (RvdH) and an EMDR consultant in training who developed the AF-EMDR protocol. The EMDR therapist (RvdH) will be trained by the EMDR consultant (WM), who is available for consultation. Additionally, both participate monthly in peer-supervision whereby videotaped sessions are discussed. See appendix 1 for a detailed understanding of the AF-EMDR protocol.
Study: NCT05989568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASIS-T
Description: BASIS-T is designed to address the behavioral components often missing from standard EBPP training and consultation that relate to motivation prior to receiving EBPP training, and volition after EBPP training. It is an EBPP-agnostic implementation strategy designed to be delivered within the Preparation/Adoption phase, immediately prior to Active Implementation (CITE EPIS). BASIS-T targets behavioral intentions via improvement in attitudes, subjective norms, and self-efficacy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control (ACC)
Description: Teachers assigned to the ACC will receive pre- and post-training experiences designed to mirror those received in the BASIS-T condition. These training experiences will be virtual, delivered by the same interventionist, and be approximately the same length as the BASIS-T experiences, but will not contain any of the BASIS-T content or mechanisms of change. The ACC pre-training experience will define, describe, and advocate for EBP implementation in schools. Content will be didactic, as is typical in professional development training for teachers.
Study: NCT06423391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuOst
Description: As above

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Intervention
Description: As above

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: As above
Study: NCT05986773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone
Description: Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
Study: NCT05823896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nirmatrelvir/ritonavir
Description: 300/100 mg tablet twice daily (q12h) administered orally for 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/ritonavir
Description: 100mg tablet twice daily (q12h) administered orally for 15 days
Study: NCT05848778

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acute Intermittent Hypoxia
Description: The acute intermittent hypoxia protocol will consist of 15 cycles of 1.5 min of inspiring ambient air (21% O2) alternating with 1.5 min of hypoxic air (9% O2)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normoxia
Description: The normoxia protocol will consist of 15 cycles of 3 min of inspiring ambient air (21% O2)
Study: NCT06102655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jiajian Guishen Formulation
Description: Jiajian Guishen Formulation is a formulation of Traditional Chinese Medicine.POI patients will be treat with Jiajian Guishen Formulation for three menstrual cycles; their blood samples are collected before and after treatment.No drug will be used in control group, and their blood samples are collected when join the experiment.
Study: NCT05068349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide
Description: Butylphthalide sodium chloride injection 25mg, 2 times a day, 7-14 days, followed by 0.2g butylphthalide soft capsules, 3 times a day, 76-83 days, a total of 90 days.
Study: NCT05987124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought(Maximum of 4 dose levels). Defibrotide will be administered in D5W or 0.9% NaCl via IV infusion over 2 hours q6 hours.
Study: NCT05111145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablets for oral administration.
Study: NCT06383221

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mental Fitness Boot Camp - Advanced Counseling Step-by-Step Care
Description: Simple and scientific advice
Study: NCT05009121

Intervention type: DIAGNOSTIC_TEST
Intervention: Box and Block Test
Description: At first, each person will be asked basic questions about present feelings according to their condition using a questionnaire. Than he/she will be tested by the Box and Block Test according to the Czech version of extended manual for this test in only one session. Audio recording of verbal instructions will be used.~The results will be used only for establishing of the variability and inter-rater reliability of the Box and Block Test, not for patients' other interventions.
Study: NCT05572450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious Titre 1
Description: Approximately 10\^5.5 TCID50/mL (titre may be adjusted based on stock titre)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious Titre 2
Description: Approximately 10\^4.5 TCID50/mL (titre may be adjusted based on stock titre)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious Titre 3
Description: To be determined (TBD), depending on outcome of Part A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious Titre 4
Description: TBD, depending on outcome of Part A
Study: NCT05789810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuel pressure
Description: 10-second manual pressure was applied on the insulin injection area.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: ShotBlocker device was placed in the insulin injection site by contacting the protruding surface with the skin and was kept throughout the injection. The injection was applied through the opening at the middle of the tool.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention was performed to reduce pain and fear.
Study: NCT06312345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: ciprofol injection
Description: Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug: ciprofol injection
Description: Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
Study: NCT04028921

Intervention type: OTHER
Intervention: No intervention
Description: This is a cross-sectional study; no intervention

Intervention type: OTHER
Intervention: No intervention
Description: This is a cross-sectional study; no intervention

Intervention type: OTHER
Intervention: No intervention
Description: This is a cross-sectional study; no intervention

Intervention type: OTHER
Intervention: No intervention
Description: This is a cross-sectional study; no intervention
Study: NCT06358495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Digital CBT-I is an online, six-module, self-guided CBT-I intervention. It includes videos and read information on behavioral (e.g., stimulus control, relaxation) and cognitive (e.g., restructuring, reducing arousal, and problem-solving) techniques, as well as psychoeducation (e.g., sleep hygiene). Participants complete homework following each session and track their sleep using an online diary. Young people could choose to involve their parents, for example, through completing sessions together. However, we will add a virtual session for parents as their involvement may improve adolescent engagement with the intervention as well as outcomes for adolescent sleep problems (Gradisar et al., 2011). This module will include an overview of the program components (behavioural, cognitive, and educational), goals and homework, and addresses parents' beliefs about sleep.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants are encouraged to continue any care they are already receiving and will be placed on a wait-list for digital CBT-I after their final assessment. All activities participants try for improving their own sleep problems between assessments will be recorded and coded for.
Study: NCT05240313

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: kiR venezolano
Description: A multi-week intervention focused on drug refusal skills and self-regulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: kiR venezolano
Description: A multi-week intervention focused on drug refusal skills and self-regulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: kiR venezolano
Description: A multi-week intervention focused on drug refusal skills and self-regulation.
Study: NCT05739760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poem book about relational health
Description: Poem book will consist of illustrations, poetry, and tips for parents on how to resolve their child's upset, their own upset, and to develop a stronger relationship. The study physician may read the book to the families at the visit. Then, families are instructed to read the book at least once, for as many times as the parent opts to.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poem book about physical health and safety
Description: Poem book will consist of illustrations, poetry, and tips for parents on how to keep their child physically healthy and safe, and to avoid accidental injuries. The study physician may read the book to the families at the visit. Then families are instructed to read the book at least once, for as many times as the parent opts to.
Study: NCT05771675

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Simvastatin Placebo tablet
Study: NCT05865080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.3 mg/kg of ketamine IV diluted to 10 ml followed by infusion 0.1 mg/kg/hr. as 20 ml solution before spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT05189210

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GV1001 Placebo
Description: 0.9% normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 0.56mg
Description: Lyophilized peptide from hTERT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 1.12mg
Description: Lyophilized peptide from hTERT
Study: NCT06110728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Change
Description: Participants assigned to the Habit Change arm will be asked to track behaviors related to their specific goals on a daily basis through the app and will be allowed to engage with the app freely. Goals can include things like reaching a step goal, sleeping for a certain number of hours, or making healthy food choices.
Study: NCT04809272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentChat for parents of children ages 2-17
Description: The programme will include text/audio messages, illustrated comics, videos, and activity assignments for parents to do with their children. Parents will be prompted to give feedback regarding successes and challenges applying these parenting skills via audio or text messages during the week.
Study: NCT04674267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 2 Intervention - Geriatric Co-Management
Description: Participants will complete an electronic fitness assessment questionnaire - once completed, they will receive a score of Robust, Pre-Frail or Frail. Those who are Pre-frail or Frail will be randomized to meet with a study geriatrician for geriatric co-management in addition to usual oncology care. All participants will be followed for a duration of 1 year.
Study: NCT05221866

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empowering patient to steer their pain management after surgery
Description: Prior to discharge from the hospital, patients will be approached regarding interest in the study with an introductory letter that describes the content and purpose of the study. Following informed consent, patients will be randomized to receive the consumer health informatics app (UControlPain) versus provision of an app with only data collection function (no educational components) in an intent-to-treat design. Randomization will be implemented via REDCap by the study coordinators so that all investigators will remain blind to group assignment. Further, information on which type of app was installed will not be shared with providers or patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empowering patient to steer their pain management after surgery
Description: Prior to discharge from the hospital, patients will be approached regarding interest in the study with an introductory letter that describes the content and purpose of the study. Following informed consent, patients will be randomized to receive the consumer health informatics app (UControlPain) versus provision of an app with only data collection function (no educational components) in an intent-to-treat design. Randomization will be implemented via REDCap by the study coordinators so that all investigators will remain blind to group assignment. Further, information on which type of app was installed will not be shared with providers or patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider-facing prescription aid
Description: Providers will be given information to inform a patient-centered post-discharge pain management plan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider-facing prescription aid
Description: Providers will be given information to inform a patient-centered post-discharge pain management plan.
Study: NCT06209489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White cover
Description: * A white cover will be covered over the incubator during phototherapy.~* Baby massage will be applied during phototherapy.
Study: NCT05261828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and rehabilitation associated with personalized follow-up
Description: short multidisciplinary program including education and rehabilitation and a personalized follow-up for patients with subacute and chronic low back pain
Study: NCT03971149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER
Description: EMPOWER includes 4 weekly home visit and 4 follow up booster phone calls every other week for the following 8 weeks. The trained nurse interventionist will address identified adherence barriers related to knowledge deficits about heart failure and its treatment including psycho-social barriers and logistic barriers with their primary care physician if necessary.
Study: NCT05841446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test apixaban tablets
Description: specification: 2.5 mg, manufacturer: Disha Pharmaceutical Group Co., Ltd., Shandong, China

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test apixaban tablets
Description: specification: 2.5 mg, manufacturer: Disha Pharmaceutical Group Co., Ltd., Shandong, China

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference apixaban tablets
Description: specification: 2.5 mg, manufacturer: Bristol-Myers Squibb Manufacturing Company, USA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference apixaban tablets
Description: specification: 2.5 mg, manufacturer: Bristol-Myers Squibb Manufacturing Company, USA
Study: NCT06229821

Intervention type: DEVICE
Group type: OTHER
Intervention: Intrapulmonary Percussive Ventilation
Description: IPV applied at increasing intervals, starting every 6 hours, and ending at every 24 hours, for a total of 7 days.
Study: NCT05261828

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reassuring messages and advices
Description: Reassuring messages and advices in agreement with current recommendations
Study: NCT04638751

Intervention type: DRUG
Intervention: Immunotherapy
Description: Checkpoint inhibitor

Intervention type: DRUG
Intervention: Immunotherapy
Description: Checkpoint inhibitor

Intervention type: DRUG
Intervention: Immunotherapy
Description: Checkpoint inhibitor

Intervention type: DRUG
Intervention: Chemotherapy
Description: Any form of chemotherapy
Study: NCT04722588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Introducing clinical pharmacists to the interdisciplinary ED team.
Description: There will be two shifts, one shift from 08.00 - 15.00 and one from 12.00 - 19.00. Consequently, the hours of the day when the majority of patients arrives, are covered and the pharmacist capacity is doubled during the busiest time of the day. Early mornings are normally relatively slowed paced and the pharmacist may use this time to follow up on patients admitted during the night (from 19.00 - 08.00), in particularly those who have been admitted to wards without an assigned pharmacist.
Study: NCT04638751

Intervention type: DRUG
Intervention: Chemotherapy
Description: Any form of chemotherapy

Intervention type: DRUG
Intervention: Chemotherapy
Description: Any form of chemotherapy

Intervention type: PROCEDURE
Intervention: CRC surgical resection
Description: Surgical resection to remove colorectal cancer

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Standard-of-care colonoscopy for CRC screening

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Standard-of-care colonoscopy for CRC screening